[{"address1": "Cedar Brook Corporate Center", "address2": "4-B Cedar Brook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 495 2200", "fax": "609 495 2202", "website": "https://palatin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl  Spana Ph.D.", "age": 61, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 979000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Burns  McClellan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen A. Slusher Esq.", "title": "Chief Legal Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Raizman M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James E. Hattersley", "age": 63, "title": "Senior Vice President of Business Development", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Dodd Ph.D.", "title": "Senior Vice President of Preclinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Jordan", "title": "Senior Vice President of Program Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.57, "open": 1.58, "dayLow": 1.55, "dayHigh": 1.66, "regularMarketPreviousClose": 1.57, "regularMarketOpen": 1.58, "regularMarketDayLow": 1.55, "regularMarketDayHigh": 1.66, "beta": 0.94, "forwardPE": -1.6875, "volume": 164362, "regularMarketVolume": 164362, "averageVolume": 581160, "averageVolume10days": 294550, "averageDailyVolume10Day": 294550, "bidSize": 1200, "askSize": 900, "marketCap": 26141292, "fiftyTwoWeekLow": 1.43, "fiftyTwoWeekHigh": 5.65, "priceToSalesTrailing12Months": 3.6830664, "fiftyDayAverage": 3.041, "twoHundredDayAverage": 2.41105, "currency": "USD", "enterpriseValue": 17477518, "floatShares": 15548298, "sharesOutstanding": 16136600, "sharesShort": 1155963, "sharesShortPriorMonth": 469110, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0716, "heldPercentInsiders": 0.03312, "heldPercentInstitutions": 0.107250005, "shortRatio": 1.38, "shortPercentOfFloat": 0.073, "impliedSharesOutstanding": 16136600, "bookValue": -0.796, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -35043960, "trailingEps": -2.98, "forwardEps": -0.96, "lastSplitFactor": "1:25", "lastSplitDate": 1661904000, "enterpriseToRevenue": 2.462, "enterpriseToEbitda": -0.572, "52WeekChange": -0.46179402, "SandP52WeekChange": 0.31995547, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PTN", "underlyingSymbol": "PTN", "shortName": "Palatin Technologies, Inc.", "longName": "Palatin Technologies, Inc.", "firstTradeDateEpochUtc": 876922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef61cf2b-791e-37b7-b04c-9ccb76a1630d", "messageBoardId": "finmb_32651", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.62, "targetHighPrice": 17.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.33, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 9485252, "totalCashPerShare": 0.588, "ebitda": -30547608, "totalDebt": 821374, "quickRatio": 1.056, "currentRatio": 1.093, "totalRevenue": 7097698, "revenuePerShare": 0.575, "returnOnAssets": -0.84773004, "returnOnEquity": -14.13302, "freeCashflow": -2026841, "operatingCashflow": -26543816, "revenueGrowth": 0.982, "grossMargins": -2.25961, "operatingMargins": -3.2694001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]